TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET)

Despite trastuzumab-based therapy, up to half of patients with HER2+ metastatic breast cancer (MBC) will develop brain metastases (BrM). First-line therapy for HER2+ MBC, taxane/trastuzumab/pertuzumab (TP), demonstrates poor brain permeability. Isolated brain relapse with stable/absent extracranial...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Swearingen, Amanda, Sammons, Sarah, Noteware, Laura, Bagegni, Nusayba, Moulton, Kelly, Threatt, Stevie, Jaggers, Denise, Shea, Shannon, Lipp, Eric, Riley, Erin, Jung, Sin-Ho, Broadwater, Gloria, Ross, Masey, Strickland, Kimberly, Beyer, Sasha, Conlin, Alison, Morikawa, Aki, Murthy, Rashmi, Anders, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Trials in Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402322/
http://dx.doi.org/10.1093/noajnl/vdad070.149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402322/
http://dx.doi.org/10.1093/noajnl/vdad070.149

Ejemplares similares